Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHAIRMAN; REDESIGNATION OF CHAIRMAN TO VICE CHAIRMAN; RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board of directors (the "**Board**") of Touyun Biotech Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces the following changes with effect from 20 November 2026:

I. Appointment of Executive Director and Chairman

Mr. Luo Dan ("**Mr. Luo**") has been appointed as an executive director of the Company and the chairman of the Board.

Mr. Luo, aged 41, holds a Master of Business Administration degree from Fudan University. He is currently the general manager of Shanghai Cooperation Organisation International Investment Group Co., Ltd. Mr. Luo has extensive experience in cross-border capital market investments. He has previously served at renowned PRC PE funds and public funds, with key industry investment focuses spanning consumer and cultural tourism, healthcare and elderly care, bio-agriculture, and energy and computing power. In 2013, he initiated and managed China's first talent fund.

Mr. Luo has entered into a service contract with the Company for a term of three years commencing from 20 November 2026, which may be terminated by either party by giving one month's written notice to the other. Pursuant to the articles of association of the Company, his appointment shall be subject to retirement by rotation and re-election at the next annual general meeting of the Company. Mr. Luo is entitled to receive a director's remuneration of HK$300,000 per month, which was determined by the remuneration committee under the Board and the Board with reference to his experience, knowledge, qualifications, duties and responsibilities, and current market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Luo: (i) has no other relationship with any other director, senior management or substantial or controlling shareholder (as defined in the Listing Rules) of the Company; (ii) does not have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance; (iii) does not hold any other position in any member of the Group; (iv) has not held any directorship in any other listed company in Hong Kong or overseas in the past three years; (v) does not have any other major appointments or professional qualifications; and (vi) does not have any other information required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor is there any other matter that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

II. Redesignation of Chairman to Vice Chairman

Mr. Wang Liang ("**Mr. Wang**") has been redesignated from the chairman of the Board to the vice chairman of the Board and will continue to serve as an executive director of the Company. Following the above redesignation, Mr. Wang serves as vice chairman of the Board alongside the existing vice chairperson Ms. Zhou Ruijuan. Mr. Wang's monthly salary has been adjusted from HK$300,000 to HK$200,000, which adjustment was determined by the Board with reference to the duties and responsibilities of his new position.

The biographical details of Mr. Wang are as follows: Mr. Wang holds a Bachelor of Science degree in Physics from Imperial College London and a Master of Science degree in International Finance from the University of Westminster, UK, and has extensive experience in international financing and project management. Mr. Wang joined the Group in December 2012, was appointed as an executive director of the Company with effect from 1 September 2016, and has served as the chairman of the Board since 23 January 2017.

III. Resignation of Non-Executive Director

Mr. Zhang Lele ("**Mr. Zhang**") has resigned as a non-executive director of the Company due to personal affairs with effect from 20 November 2026, and will continue to serve as a vice president of a subsidiary of the Company. Mr. Zhang has confirmed that there is no disagreement between him and the Board, and that there are no matters relating to his resignation that need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhang for his valuable contributions to the Company during his tenure, and to extend a warm welcome to Mr. Luo for joining the Board.

By order of the Board
Touyun Biotech Group Limited
Luo Dan
Chairman

Hong Kong, 20 November 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors
Mr. Luo Dan *(Chairman)*
Mr. Wang Liang *(Vice chairman)*
Ms. Zhou Ruijuan *(Vice chairlady)*
Mr. Du Dong

Non-executive Directors
Ms. Tian Yuze
Mr. Chen Hui

Independent Non-executive Directors
Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen